Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia
Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia
June 26, 2023 (Issue: 1679)
The FDA has approved the oral second-generation
antipsychotic drug brexpiprazole (Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated
with dementia due to Alzheimer's disease (AD).
Brexpiprazole is the first drug to be...more
- Brexpiprazole (Rexulti) for schizophrenia and depression. Med Lett Drugs Ther 2015; 57:116.
- D Lee et al. A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease. Expert Opin Pharmacother 2023; 24:691. doi:10.1080/14656566.2023.21 95539
- RR Tampi et al. Propranolol for the management of behavioural and psychological symptoms of dementia. Drugs Context 2022; 11:2022. doi:10.7573/dic.2022-8-3
- Drugs for cognitive loss and dementia. Med Lett Drugs Ther 2022; 64:129.
- GT Grossberg et al. Effi cacy and safety of brexpiprazole for the treatment of agitation in Alzheimer’s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry 2020; 28:383. doi:10.1016/j.jagp.2019.09.009
- FDA briefi ng document. Brexpiprazole. Joint meeting of the Psychopharmacologic Drugs and Peripheral and Central Nervous System Drugs Advisory Committees, April 14, 2023. Available at https://bit.ly/3IVsHdJ. Accessed June 8, 2023.
- Drugs for psychotic disorders. Med Lett Drugs Ther 2016; 58:160.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. June 5, 2023. Reprinted with permission by First Databank, Inc. All rights reserved. ©2023. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia
Article code: 1679b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
